SK Bioscience and Vaxxas partner to develop needle-free typhoid vaccine patch
The companies received a $3.67m grant to develop a low-cost, temperature-stable vaccine to improve market access in developing countries.
The companies received a $3.67m grant to develop a low-cost, temperature-stable vaccine to improve market access in developing countries.
What's Your Reaction?
